Colorectal Cancer Clinical Trials & Research at Providence Medical Group

Pancreatic Cancer

Colorectal cancer is the third most common type of cancer in men and women in the U.S. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer.

Providence Medical Group is currently enrolling patients for the following colorectal cancer clinical trials:


1st-2nd line HER2-, CPS<5

Study Coordinator: Camille
initially 1 prior Rx ok but later will be 1st line, predominantly adeno so GEJ and distal esoph ok, >6mos from completing adj
Rx: Dato-DXd + 5FU or cape

Colorectal Cancer

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Treatment agent: Duloxetine
PI: Sara Keck, MD
Study Coordinator: Melissa Phillips // (707) 521-3833
Resources and Links:
Sponsor: Alliance for Clinical Trials in Oncology with National Cancer Institute

A2211805: Randomized Placebo Controlled, Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy (a PCRC study)

Study Coordinator: Melissa Phillips // (707) 521-3833
Stage 2-3 CRC, planning adjuvant FOLFOX (3-6mos) or CAPOX (3mos), no prior neurotoxic chemo or prexisting neuropathy

MOUTAINEER-03: Randomized Ph 3 Tucatinib + Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab 1L HER2+ Met CRC

Study Coordinator: Teresa x1103
HER2+ RAS wt, 1:1 randomization

Our Providers

Our Locations